Lilly(Eli) is trading with a PEG ratio of 0.32, based on Jul 31, 2026 data. Dividing the 40.75 PE ratio by the 128.4% earnings growth rate yields this valuation metric. Relative to the 0.41 average from the previous four quarters, the PEG ratio has decreased by 21%.
Historically, Lilly(Eli) shows a PEG ratio averaging 6.38 across the past ten years. At 0.32, today's PE to growth ratio sits 95% below its historical average. The ten years high occurred in the Mar 2022 quarter at 60.51, reflecting maximum valuation relative to growth. The minimum was hit in the Jun 2019 quarter at 0, indicating optimal value relative to growth during that period.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.49 | 46.73 | 95.6% |
| 2024 | 0.64 | 65.65 | 102.1% |
| 2023 | N/A | 100.16 | -16% |
| 2022 | 4.16 | 52.79 | 12.7% |
| 2021 | N/A | 44.91 | -9.8% |
| 2020 | N/A | 24.76 | -23.6% |
| 2019 | 0.08 | 14.72 | 184.4% |
| 2018 | 0.02 | 36.85 | 1,752.6% |
| 2017 | N/A | N/A | -107.3% |
| 2016 | 2.01 | 28.4 | 14.1% |
| 2015 | 20.62 | 37.12 | 1.8% |
| 2014 | N/A | 30.94 | -48.5% |
| 2013 | 0.65 | 11.78 | 18% |
| 2012 | N/A | 13.44 | -5.9% |
| 2011 | N/A | 10.66 | -14.8% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Mar 2026 | 0.25 | 32.63 | 128.4% |
| Dec 2025 | 0.49 | 46.73 | 95.6% |
| Sep 2025 | 0.31 | 37.24 | 120.6% |
| Jun 2025 | 0.58 | 50.78 | 88.3% |
| Mar 2025 | 0.83 | 66.93 | 80.9% |
| Dec 2024 | 0.64 | 65.65 | 102.1% |
| Sep 2024 | 1.41 | 95.36 | 67.7% |
| Jun 2024 | 8.55 | 111.09 | 13% |
| Mar 2024 | 14.08 | 114.07 | 8.1% |
| Dec 2023 | N/A | 100.16 | -16% |
| Sep 2023 | N/A | 96.95 | -17.1% |
| Jun 2023 | 4.46 | 65.05 | 14.6% |
| Mar 2023 | N/A | 54.42 | -6.7% |
| Dec 2022 | 4.16 | 52.79 | 12.7% |
| Sep 2022 | 28.48 | 48.41 | 1.7% |
Measured against past performance, LLY's PEG ratio is below the 3, 5 and 10-year averages.
Lilly(Eli)'s PEG of 0.32 is below the Healthcare sector and the industry average. Compared to its Healthcare sector average of 0.56, Lilly(Eli)'s PEG is 43% lower.
Compared to its peers, LLY has a PEG ratio under stocks AZN and AMGN, while above BMY's.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| BMY Bristol-Myers Squibb Company | 0.17 | $131.84B |
| LLY Lilly(Eli) & Company | 0.31 | $1.06T |
| AMGN AMGEN Inc | 0.85 | $206.25B |
| AZN Astrazeneca plc | 0.89 | $241.13B |
| MRK Merck & Co Inc | N/A | $316.38B |
| JNJ Johnson & Johnson | N/A | $607.73B |
| PFE Pfizer Inc | N/A | $142.37B |
| ABBV Abbvie Inc | N/A | $434.75B |
| NVS Novartis AG | N/A | $293.47B |
Based on Jul 31, 2026 data, LLY carries a PEG ratio of 0.32.
Over the last 3 years, LLY's PEG ratio has settled near 3.02.
Over the last 5 years, LLY's PEG ratio has settled near 9.28.
The Mar 2022 quarter marked the ten years high at 60.51 for LLY's PEG ratio.
Compared to the 10-year average, LLY's PEG ratio is 95% lower.
The 0.32 PEG ratio for LLY reflects strong earnings growth outpacing the current valuation.
The PEG ratio comes from taking PE and dividing by the rate at which earnings are growing (YoY TTM). As of Jul 31, 2026, Lilly(Eli) has a P/E ratio of 40.75. Earnings grew at 128.4% over the TTM period ending Mar 2026. Applying the formula, this produces a price to earnings growth ratio of 0.32. PEG RATIO(0.32) = PE RATIO(40.75) / EPS GROWTH(128.4%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.